Evolving Drugs to Target Evolving Diseases
From influenza to cancers, state-of-the-art therapies and vaccines are static compounds. Unfortunately, these static interventions are used to treat evolving diseases.
Faced with mutating disease targets, new interventions (e.g., annual flu vaccines) must be developed and distributed each time a disease evolves resistance. Each new drug requires billions of dollars and a decade to develop. In many cases, new therapies cannot be developed in time to save patients from drug-resistant infections and cancers.
Our goal is to develop the first therapeutics that evolve along with mutating diseases—enabling lifelong, ‘resistance-proof’ control. Imagine taking a flu vaccine once in your life and never worrying about the flu again.